Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Profit is expected to fall below the initial forecast due to the contraction of the throat lozenge market and slowing growth in the gummy market during the first half, higher raw material prices and energy costs, cost increases resulting from the situation in the Middle East, a timing mismatch with product price revisions, and investment for future growth. These effects are also expected to continue in the second half.
| Item | Details |
|---|---|
| Net Sales | ¥36,500 million → ¥36,500 million（0.0%） |
| Operating profit | ¥4,900 million → ¥4,200 million（-14.3%） |
| Ordinary income | ¥4,900 million → ¥4,200 million（-14.3%） |
| Profit attributable to owners of the parent | ¥3,450 million → ¥3,000 million（-13.0%） |
| Net income per share | ¥81.87 → ¥71.12 |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Net sales of ¥34,771 million, operating profit of ¥4,691 million, ordinary profit of ¥4,746 million, net income attributable to owners of the parent of ¥3,378 million, and earnings per share of ¥80.18 (fiscal year ended December 2025) |
| Reason for the revision | Profit is expected to fall below the initial forecast due to the contraction of the throat lozenge market and slowing growth in the gummy market during the first half, higher raw material prices and energy costs, cost increases resulting from the situation in the Middle East, a timing mismatch with product price revisions, and investment for future growth. These effects are also expected to continue in the second half. |
| Dividend forecast revision | No change (the year-end dividend for the current fiscal year remains unchanged at ¥18 per share) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reasons cited include the contraction of the throat lozenge market and slowing growth in the gummy market during the first half, higher raw material prices and energy costs, cost increases resulting from the situation in the Middle East, a timing mismatch with product price revisions, and investment for future growth. Cost increases are expected to continue in the second half, and the company believes that the contribution margin from higher sales will not be sufficient to absorb all cost increases and growth investments.